Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the ...

Shares of Merck & Co. Inc. MRK slipped 1.43% to $113.09 Thursday, on what proved to be an all-around favorable trading ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2024年9月19日，“医药一哥”恒瑞医药宣布，其自主研发的创新药瑞拉芙普-α注射液（SHR-1701）的药品上市许可（金麒麟分析师）申请，已经获国家药监局受理，适应症为：本品联合 ...

When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses ...

圣安生医(6926)以创新HLA-G标靶外泌体药物递送平台(SOB100)系列药物的研发，荣获第11届默克(Merck)特别奖。默克全球新兴生物科技资助项目于2014年启动，虽然每年提供全球不同区域的生技公司申请，这是继2019年第一次 ...

这一价格异常波动引起了官方的关注。2023年11月6日，地塞米松磷酸钠注射液被纳入第九批国家药品集采，中选价格骤降至0.23元/支，降幅高达98%。受此影响，2024年一季度，地塞米松磷酸钠注射剂在国内院内市场的销售额同比下滑了47.8%。即便未中选 ...

Merck & Co Inc. (MRK) on Wednesday said its Phase 3 KEYFORM-007 study evaluating the company's drug candidate favezelimab in ...